Intensity Therapeutics, Inc. Common stock
$4.11
$0.23 (+5.93%)
$3.79Day Range$4.29
Key Statistics
Market Cap
$13.42M
Shares Outstanding
3.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 30, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$3.79
Day High
$4.29
Day Low
$3.79
Volume
45.2K
VWAP
$4.03
Prev Close
$3.88
Transactions
--
Acc. Volume
--
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 28367 employees1 ENTERPRISE DRIVE, SUITE 430, SHELTON, CT, 06484203-221-7381IPO Jun 30, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001567264
- Composite FIGI
- BBG00B57FZV6
- Share Class FIGI
- BBG00B57FZW5
- Ticker Root
- INTS
- SIC Code
- 2836
About Intensity Therapeutics, Inc. Common stock (INTS) Stock
Intensity Therapeutics, Inc. Common stock (INTS) closed the 2026-09-18 session at $4.11, up 5.93% versus the previous close (+0.23). The stock opened at $3.79 and traded between $3.79 and $4.29 during that session. Session trading volume was 45K shares. The volume-weighted average price (VWAP) is $4.03.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Intensity Therapeutics, Inc. Common stock has a market capitalization of $13.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. INTS is listed on the XNAS exchange. The company employs approximately 7 people. Intensity Therapeutics, Inc. Common stock is headquartered in SHELTON, CT. The recorded listing date is 2023-06-30.
On this page you can find market INTS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.